Since 2012, ponatinib has been approved as treatment for CP-CML, AP-CML, and BP-CML, and Ph+ ALL resistant or intolerant to TKIs and has a large clinical data set (N = 553) supporting its efficacy (46% CCyR by 12 months in PACE; 52% ≤1% BCR::ABL1IS by 12 months in OPTIC) [4, 21] and safety in this highly resistant population [22, 23]. Here, BCR is linked to acute lymphoblastic leukemia.